As­traZeneca says it is prun­ing staff at Med­Im­mune, its bi­o­log­ics R&D cen­ter

9 years ago
R&D

FDA re­view de­tails sui­cides, car­dio risks linked to Valeant’s $100M drug bro­dalum­ab

9 years ago
R&D

Q2 ven­ture in­vest­ing slows a tad, but the big mon­ey still flows in­to biotech

9 years ago
Financing
R&D

CAR-T play­er Juno grabs a PhII com­bo drug in $10M add-on deal

9 years ago
R&D

Mar­tin Shkre­li will have his day(s) in court - next June

9 years ago
People

Kad­mon sticks a $100M toe in chilly mar­ket wa­ters

9 years ago
R&D

San­thera’s Duchenne drug hits a road­block at the FDA, and one an­a­lyst sees an­oth­er bad sign for Sarep­ta

9 years ago
R&D

And then there were 4: Juno adds an­oth­er vic­tim in CAR-T death tal­ly

9 years ago
R&D

Po­laris is piec­ing to­geth­er a new, $400M-plus biotech fund as good times roll

9 years ago
R&D

Biosim­i­lars go 2-0 in an FDA dou­ble-head­er fa­vor­ing No­var­tis, Am­gen

9 years ago
R&D

The 15 top R&D spenders in the glob­al bio­phar­ma busi­ness: 2016

9 years ago
R&D
Special

Mer­ck vet Michael Rosen­blatt joins R&D ex­o­dus to the start­up world

9 years ago
R&D

Periscope: Un­suc­cess­ful on Nas­daq, Gen­Sight finds a home on Paris ex­change

9 years ago
R&D

Ex-Bio­gen ex­ec Steve Holtz­man hears the call of Third Rock’s am­bi­tious Deci­bel

9 years ago
People
Startups

In a stun­ner, FDA im­me­di­ate­ly drops its hold on Juno’s lead CAR-T

9 years ago
R&D

FDA ex­perts unan­i­mous­ly en­dorse Am­gen’s biosim­i­lar of Ab­b­Vie’s $14B fran­chise drug

9 years ago
Pharma

Mer­ck trig­gers a new round of lay­offs in R&D re­or­ga­ni­za­tion, push­ing more jobs in­to Cam­bridge, San Fran­cis­co

9 years ago
R&D

Sage claims an­oth­er big win on a small study, this time for post­par­tum de­pres­sion

9 years ago
R&D

$42M in, Flag­ship star­tups merge in­to one im­muno-mi­cro­bio­me plat­form with mul­ti­ple tar­gets

9 years ago
Startups
R&D

Shire gains a de­layed FDA OK for ‘block­buster’ dry eye drug li­fite­grast

9 years ago
R&D

CytRx con­cedes that its on­ly drug flunked a PhI­II sar­co­ma test, rout­ing shares

9 years ago
R&D

Knock it off: Biosim­i­lars are not a 'knock­of­f' drug

9 years ago
Bioregnum
Pharma

Periscope: Ex-Bax­al­ta ex­ec David Meek takes Paris-based helm for Ipsen

9 years ago
R&D

I/O en­thu­si­ast Servi­er signs up for an $807M, sec­ond wave PD-1 de­vel­op­ment deal with Sor­ren­to

9 years ago
R&D
First page Previous page 1174117511761177117811791180 Next page Last page
A service from the Financial Times